# ‘I don’t want to go to opioids’: Texans worry about managing chronic pain amid hemp crackdown > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/opioid-alternatives-chronic-pain-texas-hemp-crackdown/ > **Published:** 2026-03-30T22:03:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:34:30-04:00 > **Clinical Summary:** Explore opioid alternatives chronic pain management challenges Texans face amid hemp crackdown and regulatory changes impacting treatment access. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic [Chronic Pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/)Hemp PolicyOpioid AlternativesTreatment Access[Pain Management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) Why This Matters Access restrictions to hemp-derived products force patients with [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) into a difficult clinical position between potentially less effective alternatives and opioid therapy they wish to avoid. This highlights the real-world impact of regulatory changes on established [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) protocols. Clinical Summary Texas patients using hemp-derived cannabinoids for [chronic pain management](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) are expressing concern about losing access to these products due to regulatory crackdowns. Many report preferring hemp products over opioid medications for pain control, citing concerns about opioid dependence and side effects. The regulatory uncertainty creates treatment discontinuity for patients who have found benefit with hemp-derived products, potentially forcing them toward conventional pain medications they previously avoided. Dr. Caplan’s Take “When patients tell me they’re managing pain effectively with hemp products and avoiding opioids, that’s a clinical win worth preserving. Regulatory changes that force patients back to treatments they’ve specifically chosen to avoid create unnecessary therapeutic regression.” Clinical Perspective 🧠 Clinicians should proactively discuss contingency pain management plans with patients currently using hemp products, documenting their treatment history and effectiveness. Consider transitioning patients to pharmaceutical cannabinoids where available and appropriate, or exploring other non-opioid pain management strategies before regulatory changes force abrupt discontinuation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%27I%20don%27t%20want%20to%20go%20to%20opioids%27%3A%20Texans%20worry%20about%20managing%20chronic%20pain%20amid%20h...%20%40drcaplan&url=https%3A//www.youtube.com/watch%3Fv%3D4w1SwgNDX1M)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.youtube.com/watch%3Fv%3D4w1SwgNDX1M)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%27I%20don%27t%20want%20to%20go%20to%20opioids%27%3A%20Texans%20worry%20about%20managing%20chronic%20pain%20amid%20h...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.youtube.com/watch%3Fv%3D4w1SwgNDX1M)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.youtube.com/watch?v=4w1SwgNDX1M](https://www.youtube.com/watch?v=4w1SwgNDX1M) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What medical conditions does this cannabis news relate to?](#What_medical_conditions_does_this_cannabis_news_relate_to) - [How does this relate to current opioid treatment approaches?](#How_does_this_relate_to_current_opioid_treatment_approaches) - [What policy aspects are covered in this article?](#What_policy_aspects_are_covered_in_this_article) - [Who should pay attention to this cannabis news?](#Who_should_pay_attention_to_this_cannabis_news) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What medical conditions does this cannabis news relate to? The article focuses primarily on [chronic pain management](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/). It appears to discuss cannabis as a potential treatment option for patients suffering from persistent pain conditions. #### How does this relate to current opioid treatment approaches? The content is tagged as covering “Opioid Alternatives,” suggesting it discusses cannabis as a potential substitute or complementary treatment to traditional opioid medications. This is particularly relevant given current concerns about opioid dependency and addiction. #### What policy aspects are covered in this article? The article includes hemp policy developments that may affect patient access to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). These policy changes could impact how healthcare providers can recommend or prescribe cannabis products for medical use. #### Who should pay attention to this cannabis news? Healthcare providers treating chronic pain patients should monitor this information closely. The “Notable Clinical Interest” rating indicates this could influence treatment decisions and patient access to [alternative pain management](https://cedclinic.com/full-spectrum-cannabis-extract-chronic-neuropathic-pain-relief/) options. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “‘I don’t want to go to opioids’: Texans worry about managing chronic pain amid hemp crackdown”, “url”: “https://www.youtube.com/watch?v=4w1SwgNDX1M”, “datePublished”: “2026-03-30T23:05:50Z”, “about”: “i don t want go opioids”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Texas bans smokable hemp cannabis products – KXAN Austin](https://cedclinic.com/texas-smokable-hemp-ban-patient-access/) Learn about the recent Texas ban on smokable hemp products and its impact on patients and retailers. [Read More](https://cedclinic.com/texas-smokable-hemp-ban-patient-access/) [Judge rules to temporarily block Texas' smokeable hemp ban | KXAN Austin](https://cedclinic.com/temporary-injunction-texas-hemp-ban/) Stay updated on the legal developments temporarily blocking Texas' smokeable hemp ban. [Learn More](https://cedclinic.com/temporary-injunction-texas-hemp-ban/) [Texas hemp industry hopeful to continue operation amid pause on THC ban](https://cedclinic.com/texas-hemp-industry-regulation-operational-pause/) Explore how the Texas hemp industry is adapting amid regulatory pauses on THC bans. [Discover More](https://cedclinic.com/texas-hemp-industry-regulation-operational-pause/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).